← Back to patent-cliff list
Anti-GD2-800CW
Tier C — Watch / tradeAnti-GD2-800CW
Princess Maxima Center for Pediatric Oncology
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GD2
Indications (approved)：Neuroblastoma
Regional status
US
-
EU
Phase II
2025-11-05
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Anti-GD2-800CW?
Approved indications include: Neuroblastoma.
When does the Anti-GD2-800CW patent expire?
No public expiry year is available for Anti-GD2-800CW yet; this page updates once verified.
How do I get a quote for Anti-GD2-800CW intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30